Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis
Abstract
1. Introduction
2. Patients and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Perez-Chada, L.M.; Merola, J.F. Comorbidities associated with psoriatic arthritis: Review and update. Clin. Immunol. 2020, 214, 108397. [Google Scholar] [CrossRef] [PubMed]
- Ogdie, A.; Schwartzman, S.; Husni, M.E. Recognizing and managing comorbidities in psoriatic arthritis. Curr. Opin. Rheumatol. 2015, 27, 118–126. [Google Scholar] [CrossRef] [PubMed]
- AlJohani, R.; Polachek, A.; Yang, Y.J.; Chandran, V.; Gladman, D.D. Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia. J. Rheumatol. 2018, 45, 213–217. [Google Scholar] [CrossRef] [PubMed]
- Bruce, I.N.; Schentag, C.T.; Gladman, D.D. Hyperuricemia in psoriatic arthritis: Prevalence and associated features. J. Clin. Rheumatol. 2000, 6, 6–9. [Google Scholar] [CrossRef]
- Liu, Y.; Zhao, Q.; Yin, Y.; McNutt, M.A.; Zhang, T.; Cao, Y. Serum levels of IL-17 are elevated in patients with acute gouty arthritis. Biochem. Biophys. Res. Commun. 2018, 497, 897–902. [Google Scholar] [CrossRef]
- Raucci, F.; Iqbal, A.J.; Saviano, A.; Minosi, P.; Piccolo, M.; Irace, C.; Caso, F.; Scarpa, R.; Pieretti, S.; Mascolo, N.; et al. IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation. Pharmacol. Res. 2019, 147, 104351. [Google Scholar] [CrossRef]
- Tripolino, C.; Ciaffi, J.; Ruscitti, P.; Giacomelli, R.; Meliconi, R.; Ursini, F. Hyperuricemia in Psoriatic Arthritis: Epidemiology, Pathophysiology, and Clinical Implications. Front. Med. 2021, 8, 737573. [Google Scholar] [CrossRef]
- Rahimi-Sakak, F.; Maroofi, M.; Rahmani, J.; Bellissimo, N.; Hekmatdoost, A. Serum uric acid and risk of cardiovascular mortality: A systematic review and dose-response meta-analysis of cohort studies of over a million participants. BMC Cardiovasc. Disord. 2019, 19, 218. [Google Scholar] [CrossRef]
- Maloberti, A.; Giannattasio, C.; Bombelli, M.; Desideri, G.; Cicero, A.F.G.; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project. High Blood Press. Cardiovasc. Prev. 2020, 27, 121–128. [Google Scholar] [CrossRef]
- Gois, P.H.F.; Souza, E.R.M. Pharmacotherapy for hyperuricaemia in hypertensive patients. Cochrane Database Syst. Rev. 2020, 9, CD008652. [Google Scholar] [CrossRef]
- Ogdie, A.; Coates, L.C.; Gladman, D.D. Treatment guidelines in psoriatic arthritis. Rheumatology 2020, 59 (Suppl. 1), i37–i46. [Google Scholar] [CrossRef] [PubMed]
- Taylor, W.; Gladman, D.; Helliwell, P.; Marchesoni, A.; Mease, P.; CASPAR Study Group. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 2006, 54, 2665–2673. [Google Scholar] [CrossRef] [PubMed]
- Simons, N.; Degboé, Y.; Barnetche, T.; Cantagrel, A.; Ruyssen-Witrand, A.; Constantin, A. Biological DMARD efficacy in psoriatic arthritis: A systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes. Clin. Exp. Rheumatol. 2020, 38, 508–515. [Google Scholar] [PubMed]
- Civeira, F.; Arca, M.; Cenarro, A.; Hegele, R.A. A mechanism-based operational definition and classification of hypercholesterolemia. J. Clin. Lipidol. 2022, 16, 813–821. [Google Scholar] [CrossRef]
- Pejic, R.N.; Lee, D.T. Hypertriglyceridemia. J. Am. Board Fam. Med. 2006, 19, 310–316. [Google Scholar] [CrossRef]
- Tsuruta, N.; Imafuku, S.; Narisawa, Y. Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. J. Dermatol. 2017, 44, 1349–1352. [Google Scholar] [CrossRef]
- Galozzi, P.; Oliviero, F.; Scanu, A.; Lorenzin, M.; Ortolan, A.; Favero, M.; Doria, A.; Ramonda, R. Acute joint swelling in psoriatic arthritis: Flare or “psout”-A 10-year-monocentric study on synovial fluid. Exp. Biol. Med. 2022, 247, 1650–1656. [Google Scholar] [CrossRef]
- Page, S.; Powell, D.; Benboubetra, M.; Stevens, C.R.; Blake, D.R.; Selase, F.; Wolstenholme, A.J.; Harrison, R. Xanthine oxidoreductase in human mammary epithelial cells: Activation in response to inflammatory cytokines. Biochim. Biophys. Acta 1998, 1381, 191–202. [Google Scholar] [CrossRef]
- Zhao, Z.; Cai, L.; Zhang, S.; Zhang, H.; Liu, X.; Li, C.; Zhao, Y.; Zhang, J. Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis. Chin. Med. J. 2022, 135, 1438–1443. [Google Scholar] [CrossRef]
- Hagino, T.; Saeki, H.; Fujimoto, E.; Kanda, N. Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis. J. Clin. Med. 2023, 12, 1934. [Google Scholar] [CrossRef]
- Hasikova, L.; Pavlikova, M.; Hulejova, H.; Kozlik, P.; Kalikova, K.; Mahajan, A.; Herrmann, M.; Stiburkova, B.; Zavada, J. Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. Rheumatol. Int. 2019, 39, 1749–1757. [Google Scholar] [CrossRef] [PubMed]
- Sargın, B.; Gürer, G.; Taşcı Bozbaş, G.; Öztürk, H. Association between serum uric acid and inflammation markers in ankylosing spondylitis patients treated with tumor necrosis factor-α or nonsteroidal anti-inflammatory drugs. Eur. Res. J. 2019, 5, 104–108. [Google Scholar] [CrossRef]
- Li, X.; Miao, X.; Wang, H.; Wang, Y.; Li, F.; Yang, Q.; Cui, R.; Li, B. Association of Serum Uric Acid Levels in Psoriasis: A Systematic Review and Meta-Analysis. Medicine 2016, 95, e3676. [Google Scholar] [CrossRef]
- Hu, M.; Wang, Y.; Xu, W.; Bai, J.; Tang, X. The impact of serum uric acid on psoriasis: NHANES 2005-2014 and Mendelian randomization. Front. Genet. 2024, 9, 1334781. [Google Scholar] [CrossRef]
- Zhao, D.; Zhao, J.R.; Wang, S.; Sun, J.H. Evaluating causal influence of serum uric acid on psoriasis via observational study and transethnic Mendelian randomization analyses. Sci. Rep. 2024, 14, 26332. [Google Scholar] [CrossRef]
- Kumthekar, A.; Ogdie, A. Obesity and Psoriatic Arthritis: A Narrative Review. Rheumatol. Ther. 2020, 7, 447–456. [Google Scholar] [CrossRef]
- Jamnitski, A.; Symmons, D.; Peters, M.J.; Sattar, N.; McInnes, I.; Nurmohamed, M.T. Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review. Ann. Rheum. Dis. 2013, 72, 211–216. [Google Scholar] [CrossRef]
- Wu, J.J.; Sundaram, M.; Cloutier, M.; Gauthier-Loiselle, M.; Guérin, A.; Singh, R.; Ganguli, A. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study. J. Am. Acad. Dermatol. 2018, 79, 60–68. [Google Scholar] [CrossRef]
- Angel, K.; Provan, S.A.; Fagerhol, M.K.; Mowinckel, P.; Kvien, T.K.; Atar, D. Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: A controlled study. Am. J. Hypertens. 2012, 25, 644–650. [Google Scholar] [CrossRef]
- Liu, C.; Zhen, Y.; Zhao, Q.; Zhai, J.L.; Liu, K.; Zhang, J.X. Prednisone lowers serum uric acid levels in patients with decompensated heart failure by increasing renal uric acid clearance. Can. J. Physiol. Pharmacol. 2016, 94, 797–800. [Google Scholar] [CrossRef]
Diseases | Medications |
---|---|
Skin psoriasis without joint affection | Alopurinol |
Rheumatoid arthritis | Febuxostat |
Spondyloarthritis | Colchicine |
Ankylosing spondylitis | Pegloticase |
Reactive arthritis | Probenecid |
Arthritis associated with inflammatory bowel disease | Uricase |
Adults with juvenile idiopathic arthritis | |
Systemic lupus erythematosus | |
Sjögren’s syndrome | |
Inflammatory myopathies | |
Systemic sclerosis | |
Systemic vasculitis | |
Sarcoidosis |
Total (n = 87) | Females (n = 46) | Males (n = 41) | |
---|---|---|---|
Age, mean (S.D. 1), years | 53.9 (11.5) | 54.9 (12.5) | 52.7 (10.3) |
PsA 2 duration, mean (S.D.), years | 10.8 (7.2) | 10.9 (7.5) | 10.6 (6.9) |
BMI, mean (S.D.), kg/m2 | 27.7 (4.1) | 27.8 (4.4) | 27.5 (3.7) |
Normal BMI 3 | 24 (27.6) | 15 (32.6) | 9 (21.9) |
Overweight BMI | 39 (44.8) | 18 (39.1) | 21 (51.2) |
Obese BMI | 24 (27.6) | 13 (28.3) | 11 (26.8) |
Hypercholesterolemia | 53 (60.9) | 27 (58.7) | 26 (63.4) |
Hypertriglyceridemia | 33 (37.9) | 13 (28.3) | 20 (48.8) |
Arterial hypertension | 52 (59.8) | 28 (60.9) | 24 (58.5) |
Type 2 diabetes | 16 (18.4) | 8 (17.4) | 8 (19.5) |
Cardiovascular comorbidities | 10 (11.5) | 6 (13.1) | 4 (9.8) |
Smoking | 5 (5.8) | 5 (10.9) | 0 (0) |
Therapy Option | Patients (n = 87) | |
---|---|---|
TNFα inhibitors | Adalimumab | 14 (16.1) |
Etanercept | 11 (12.6) | |
Golimumab | 14 (16.1) | |
Infliximab | 11 (12.6) | |
Certolizumab pegol | 2 (2.3) | |
IL-17 inhibitors | Secukinumab | 25 (28.7) |
Ixekizumab | 10 (11.5) | |
csDMARD | Methotrexate | 43 (49.4) |
Leflunomide | 19 (21.8) | |
Sulfasalazine | 7 (8.1) | |
Two or more csDMARDs | 10 (11.5) | |
Low-dose glucocorticoid (≤7.5 mg prednisolone) | 28 (32.2) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Perković, D.; Petrić, M.; Maleš, M.; Erceg Maleš, I.; Radić, M. Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis. Curr. Issues Mol. Biol. 2025, 47, 142. https://doi.org/10.3390/cimb47030142
Perković D, Petrić M, Maleš M, Erceg Maleš I, Radić M. Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis. Current Issues in Molecular Biology. 2025; 47(3):142. https://doi.org/10.3390/cimb47030142
Chicago/Turabian StylePerković, Dijana, Marin Petrić, Maja Maleš, Ivana Erceg Maleš, and Mislav Radić. 2025. "Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis" Current Issues in Molecular Biology 47, no. 3: 142. https://doi.org/10.3390/cimb47030142
APA StylePerković, D., Petrić, M., Maleš, M., Erceg Maleš, I., & Radić, M. (2025). Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis. Current Issues in Molecular Biology, 47(3), 142. https://doi.org/10.3390/cimb47030142